In the quest for groundbreaking treatments for Amyotrophic Lateral Sclerosis (ALS) and Motor Neuron Disease (MND), Fandachem emerges as a beacon of innovation with SPG302. This novel medicine, with the CAS number 2274723-90-7, is set to redefine ALS drug treatment. In this comprehensive guide, we will delve into the specifications, molecular composition, and the promising role SPG302 plays as a new hope for ALS patients.

Unveiling Fandachem SPG302

Product Specifications:

• Product Name: Fandachem SPG302
• CAS Number: 2274723-90-7
• INCI or IUPAC Name: Phenylbenzothiazole-PEG4-OH
• Molecular Formula: C21H25NO5S
• Formula Weight: 403.49
• Synonyms: Fandachem spg302, fandachem spg-302, SPG302 buy online, buy SPG302 for sale by Fandachem, SPG302 for sale Hong Kong, SPG302 for sale Mong Kok, SPG302 price usd$, buy SPG-302 for sale, SPG302; SPG-302; new medicine for ALS, new ALS drug, oral ALS treatment, SPG-302 SPG302 buy, SPG-302 SPG302 price, SPG-302 SPG302 for sale, SPG-302 SPG302 manufacturer distributor supplier, buy spg302 spg-302, SPG302 for ALS patients; Phenylbenzothiazole-PEG4-OH cas 2274723-90-7; oral ALS therapy SPG302 for MND from Fandachem; Buy Fandachem SPG302 novel drug SPG-302 cas 2274723-90-7; Phenylbenzothiazole-PEG4-OH; 2-(2-(2-(2-(4-BENZOTHIAZOL-2-Y1-PHENOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHANOL; ETHANOL, 2-(2-(2-(2-(4-(2-BENZOTHIAZOLYL)PHENOXY)ETHOXY)ETHOXY)ETHOXY)-
• Appearance: Solid
• Assay: ≥97%
• Package: 20g
• Use: New drug for ALS, MND

Understanding SPG302's Molecular Composition:

Fandachem SPG302, with the IUPAC name Phenylbenzothiazole-PEG4-OH, boasts a molecular formula of C21H25NO5S and a formula weight of 403.49. The compound, also known by synonyms such as Fandachem spg302 and fandachem spg-302, is formulated to make a significant impact in the realm of ALS treatment.

Key Features and Applications:

• Novel ALS Drug: SPG302 is positioned as a new and innovative drug for ALS, bringing hope to patients grappling with this challenging condition.
• High Purity: The product is guaranteed to have an assay of 97% or higher, ensuring a high level of purity critical for pharmaceutical applications.
• Oral ALS Therapy: SPG302 stands out as an oral therapy for ALS, offering a convenient and accessible treatment option for patients.

Packaging and Availability:

Fandachem understands the importance of precision and care in pharmaceutical packaging. SPG302 comes in a secure 20g package, ensuring the integrity of the product during transit and storage.

How to Purchase SPG302:

For those seeking SPG302 for ALS treatment, Fandachem provides convenient options for purchase. The product is available for online purchase, with the flexibility to buy SPG302 for sale in Hong Kong, Mong Kok, or through various authorized distributors.

The Promise of SPG302 in ALS Treatment:

Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's disease, is a progressive neurodegenerative disorder with no known cure. The emergence of SPG302 by Fandachem brings a ray of hope to ALS patients and the medical community.

Groundbreaking ALS Drug:

SPG302 is positioned as a groundbreaking drug specifically designed for ALS treatment. Its unique composition and oral therapy format set it apart in the landscape of ALS medications.

New Medicine for ALS and MND:

Beyond its role in ALS treatment, SPG302 is also recognized as a potential therapy for Motor Neuron Disease (MND). This broadens the scope of its application, offering a potential solution for a wider range of patients.

Manufacturer's Commitment:

Fandachem, as the manufacturer and distributor of SPG302, is committed to ensuring the quality, purity, and efficacy of the product. The 5-year warranty further attests to the confidence placed in SPG302 as a reliable ALS drug.

Global Accessibility:

Fandachem's strategic distribution and online availability make SPG302 accessible globally. Patients and healthcare professionals worldwide can explore the potential of this novel ALS drug.

Scientific Insights:

Scientifically, SPG302, with the INCI name Phenylbenzothiazole-PEG4-OH, operates as a phenylbenzothiazole derivative. Its unique composition and mode of action make it a promising candidate for the development of ALS drugs. The compound's potential lies in its ability to address specific molecular targets associated with ALS pathogenesis.

Future Prospects and Research:

As SPG302 enters the realm of ALS treatment, ongoing research and clinical trials are essential to further validate its efficacy and safety. Fandachem, as the manufacturer, is likely to invest in continued research to enhance the understanding of SPG302's impact on ALS and MND.

Conclusion: A New Horizon in ALS Treatment with Fandachem SPG302

In conclusion, Fandachem's SPG302 emerges as a beacon of hope for ALS patients and those affected by Motor Neuron Disease. As a novel drug, SPG302 combines innovation, accessibility, and a commitment to quality. With its unique molecular composition, high purity, and oral therapy format, SPG302 marks a new horizon in the landscape of ALS treatment. Fandachem's dedication to the development of SPG302 showcases a promising future for those seeking effective and accessible solutions for ALS and MND.